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Edited by Jesus AvilaAbstract Reduced expression of pro-apoptotic Bcl-2 family
proteins has been described in many gastrointestinal cancers,
and may play a role in tumourigenesis. The human homologue
of the pro-apoptotic Bcl-2 protein, Bfk, is predominantly ex-
pressed in tissues of the gastrointestinal tract. In colon, four
alternatively spliced isoforms were identiﬁed; of which two are
pro-apoptotic when overexpressed. In the transition from normal
tissue to tumour, pro-apoptotic Bfk isoform expression is sub-
stantially reduced in up to 80% of tumours isolated from the hu-
man gastrointestinal tract (8/10 colonic tumours and 26/37 of all
gastrointestinal tumours) compared to 3/117 tumours from out-
side the gastrointestinal tract. These data suggest that pro-apop-
totic isoforms of Bfk may help to protect against the
development of human gastrointestinal malignancy.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Gastrointestinal malignancies account for a signiﬁcant pro-
portion of all cancer deaths, with over 100000 European pa-
tients dying annually from colorectal malignancy alone.
Defects in the apoptotic program are essential for malignant
transformation and have been described in many gastrointesti-
nal malignancies. Central to the regulation of apoptosis is the
Bcl-2 family of proteins, an expanding family of pro- and anti-
apoptotic proteins that are thought to regulate apoptosis at
least in part by homo- and hetero-dimerization at the mito-
chondrial surface. This complex family of proteins is regulated
at a number of levels, including the generation of alternatively
spliced isoforms [1–3]. Bcl-2 family proteins have been impli-
cated in gastrointestinal malignancy, particularly gastric and
colorectal carcinoma. Pro-apoptotic proteins Bax and Bak
are frequently mutated in colorectal cancer [4,5], and lower lev-
els are associated with metastatic spread [6]. In contrast, high*Corresponding author. Fax: +44 114 272 1104.
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doi:10.1016/j.febslet.2005.05.050levels of anti-apoptotic proteins such as Bcl-xL are seen in
colorectal tumours [7], and antisense to Bcl-xL has been shown
to enhance responses to anti-cancer treatments [8,9].
Bfk is a weakly pro-apoptotic member of the Bcl-2 family,
recently identiﬁed in the mouse [10], where it appears to be reg-
ulated by female sex hormones, and is upregulated in mam-
mary tissue during pregnancy and lactation. We have studied
expression of human Bfk, and have identiﬁed novel splice vari-
ants with diﬀering functions. Expression of human Bfk is dys-
regulated in human gastrointestinal tumours, particularly
colorectal malignancy.2. Materials and methods
2.1. Generation of expression constructs and probes
To generate the expression constructs, PCR fragments correspond-
ing to the full open reading frame for the four isoforms were generated
from colon cDNA. The PCR products obtained were puriﬁed and TA
cloned directly into pCRII-TOPO (Invitrogen, USA). The inserts were
subcloned by restriction enzyme digestion from these constructs into
the corresponding sites of pCR3.1 (Invitrogen), and of the appropriate
pEGFP vector (Living Colors, BD Biosciences Clontech, USA). Bfk
isoform a was excised from the appropriate expression construct using
BamHI and XhoI, and a radiolabelled probe made in a standard Kle-
now reaction incorporating dCTPa 32P. and hybridized according to
the manufacturers instructions to a membrane containing normalized
cDNA from 154 tumour and corresponding normal tissues from indi-
vidual patients (Cancer Proﬁlling Array II, Cat No. 7847-1, BD Clon-
tech). The membrane was washed and exposed to autoradiograph ﬁlm.
Full details of the patients can be found in http://www.clontech.com/
clontech/techinfo/manuals/PDF/7847-1.pdf. Brieﬂy: the patients were
aged 45–73 and 8/10 were women; the tumours were adenocarcinoma
in 9/10 and 1 was a tubovillous adenoma, 7 were stage III, and one of
each was stage I, II, IV.
2.2. PCR
RNA was reverse transcribed using oligo (dT)15 primer (Promega
UK, Southampton, UK) and standard RT techniques. Pre-prepared
mRNA (Premium RNA) was from BD Biosciences Clontech. PCR
was performed according to standard protocols. The primers used
were SLRF1 (Exon 1 CTA AAA TGA AGA GCT CCC AAA)
AND SLRR1 (Exon 4 TCT TCA GCT CTC CAG ATT TTC).
2.3. Transfection and assessment of apoptosis
A549 cells (American Type Culture Collection, Manassas, VA)
were seeded in 6-well tissue culture plates at a density of 2 · 105
per/well in RPMI 1640 (Life Technologies, USA) supplemented with
10% FBS (Life Technologies). Cells were transfected 24 h later usingblished by Elsevier B.V. All rights reserved.
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marker of transfection. The presence of Green Fluorescent Protein
was examined after a further 24 h by ﬂuorescence microscopy.
Percentage of ﬂuorescent cells exhibiting characteristic morphological
features of apoptosis was assessed.
2.4. Microscopy and cell staining
HCT116 cells were seeded at 2 · 105/dish in 35 mm glass bottom cul-
ture dishes with 0.085–0.13 mm coverglass (MatTek Corporation, MA,
USA). Transfections with the appropriate ﬂuorescent constructs were
performed 24 h later as described above.
A Deltavision RT (Applied Imaging Instruments) system based
around an Olympus BX71 microscope utilizing Mercury 100 W light
source was used for image capture. Volumetric imaging was achieved
via the DV motorised XYZ stage with an axial step size of 0.2 lm. Vol-
umes were deconvolved utilizing the Deltavision Worx software.3. Results and discussion
Bfk is an interesting member of the Bcl-2 family. First iden-
tiﬁed by Coultas et al. [10], the murine protein is expressed in
uterine and mammary tissues. It is weakly pro-apoptotic when
overexpressed and its biological function remains obscure. Our
interest in human Bcl-2 family proteins and in particular the
similarities between Bfk and Bid led us to study expression
and function of human Bfk. Human Bfk mRNA is found in
cerebellum, colon, small intestine, testis and uterus (Fig. 1A).
In addition, additional PCR products are seen in colon cDNA.
Sequencing of these products reveals the presence of four iso-
forms of this protein, three of which were expressed only in co-
lon (of the tissues studied). We assigned these isoforms theFig. 1. Human Bfk expression is largely restricted to tissues of the gastrointes
was performed on pre-prepared mRNA (Premium RNA, BD Biosciences Clo
were identiﬁed in colon tissue, but only one transcript in cerebellum, small in
on the basis of the size of their protein product. The largest band seen in
organization of the bfk gene and mRNA species are shown to scale. Putative
products of Bfk isoforms. The location of the pro-apoptotic BH3 (black box
cleavage site for caspase-3 (vertical line). (D) Putative amino acid sequencesletters a–d, according to the size of the predicted protein prod-
uct. Representations of the gene and protein structures are
shown in Fig. 1B and C. The amino acid sequence of these po-
tential proteins is shown in Fig. 1D.
Isoform a (AY265861) gives rise to a 163 amino acid protein
(predicted mass 17.5 kDa), containing both the BH2 and the
BH3 domains. This is the human homologue of murine Bfk
[10]. In addition to the Bcl-2 homology domains, Bfk isoform
a contains a sequence in the N-terminal portion that it shares
with human Bid (ECIxNxLxxxFL). Human Bfk also shares
with Bid the presence of a caspase-cleavage site, although this
is absent in murine Bfk. Cleavage at this site allows removal of
the small N-terminal fragment of Bfk by caspase-3 (data not
shown). It is interesting to note that in both Bid and Bfk, cas-
pase activity would lead to removal of the N-terminal
(ECIxNxLxxxFL) motif.
Isoform b (AY265862) contains exons 1, 2 and 4 and would
encode an 88 amino acid BH3-only protein (predicted mass
9.5 kDa). This protein also encodes an N-terminal portion
identical to that of isoform a. Isoform c (AY265863) contains
exons 1, 3 and 4 and would be expected to give rise to a protein
of just 67 amino acids (predicted mass 7.5 kDa) containing no
known functional domains. The smallest isoform, isoform d
(AY265864), contains only exons 1 and 4, and codes for a po-
tential 56 amino acid protein (predicted mass 6.3 kDa) lacking
either of the complete Bcl-2 homology domains.
When overexpressed, isoform a induced moderate levels of
apoptosis, causing a 50% increase in apoptosis compared to
the background control (Fig. 2A). This is comparable to ﬁnd-
ings with the closely related protein Bcl-G [11] and with murinetinal tract, and is seen as multiple transcripts in the colon. (A) RT-PCR
ntech) from a variety of tissues. Four transcripts corresponding to Bfk
testine, testis and uterus. We refer to these transcripts as isoforms a–d,
this ﬁgure is a non-speciﬁc band, unrelated to Bfk. (B) The genomic
translation start and stop codons are indicated. (C) Potential protein
) and the BH2 domain (grey box) domains are shown, along with the
of Bfk isoforms a–d.
Fig. 2. Modulation of apoptosis and subcellular localization of Bfk
isoforms. (A) A549 cells were transfected with 4 lg pCR3.1 vector
containing the insert shown, 1 lg pEGFP as a marker of transfection,
and carrier DNA to a total of 5 lg. Bfk isoform a and isoform b
signiﬁcantly induced apoptosis compared to the empty vector control.
Results are shown as mean % increase in apoptotic morphol-
ogy + S.E.M. for four independent experiments performed in dupli-
cate. **P < 0.01; ***P < 0.001, 1-way ANOVA with Bonferroni
correction (GraphPad Prism, GraphPad Software inc., San Diego,
CA). A549 cells were transfected with 0.5 lg of the following
constructs: (B) pEGFPC1.Bfk isoform a; (C) EGFPC1.Bfk isoform
b; (D) pEGFPC1.Bfk isoform c; (E) pEGFPC1.Bfk isoform d. Images
were taken 24 h later using the Deltavision system.
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apoptosis compared to empty vector control, whereas isoform
b, a BH3-only protein, induced levels of apoptosis comparable
to those seen with isoform a. As might be predicted, the two
pro-apoptotic Bfk isoforms were those that contained a BH3
domain.
Diﬀerential subcellular compartmentalization has been
shown to be important for the regulation of Bcl-2 family mem-
bers (e.g., Bim, Bid and Bak), including regulation of splice
isoforms [3]. In order to explore the potential role of subcellu-
lar localization on the pro-apoptotic eﬀects of Bfk, N-terminal
GFP tagged constructs were generated and transfected into
A549 cells. Fig. 2B–E shows deconvolved ﬂuorescent images,
demonstrating diﬀuse ﬂuorescence throughout cells transfected
with all four GFP fusion proteins. This would suggest that
these proteins are likely to remain cytoplasmic under resting
conditions in non-apoptotic cells, although whether this re-
mains true under conditions of stimulation has not been as-
sessed. This parallels the murine data published by Coultas
et al. [10], and further extends these observations to show thatthis distribution is preserved for the alternatively spliced iso-
forms.
Because of the restriction of Bfk isoform expression to co-
lon, we examined mRNA and protein expression in a range
of colorectal carcinoma cell lines. Expression of Bfk mRNA
was reduced in a number of these lines (Fig. 3A). In order to
establish whether dysregulated Bfk expression was a factor in
in vivo human gastrointestinal tumour formation, a double
stranded radiolabelled cDNA probe for Bfk isoform a was
hybridized to a Cancer Proﬁling Array (BD Biosciences) onto
which normalized cDNA samples from 154 tumour and nor-
mal tissues from corresponding individual patients were ar-
rayed. This allows large numbers of individual human
tumours to be examined and mRNA expression compared to
corresponding normal tissue from the same patient. Bfk was
seen to be predominantly expressed in the colon, stomach, rec-
tum and the small intestine, in accordance with data already
obtained (Fig. 3B). In addition, considerable diﬀerences be-
tween normal and tumour tissue were seen; there was clear
reduction in Bfk mRNA expression in a wide range of gastro-
intestinal malignancies. In 8 of the 10 colon tumours, levels of
Bfk mRNA were reduced compared to levels in matched nor-
mal colon tissue. In some of the samples, the level of Bfk in the
tumour was barely detectable. The levels of Bfk mRNA in the
small intestine were decreased in 6 of the 7 tumour samples
compared with the levels found in normal small intestine.
Although, the amount of Bfk mRNA in the stomach was lower
than in the large and small intestine, there was a further reduc-
tion in expression in 50% of the tumour samples. All the rectal
samples expressed Bfk and downregulation was observed in 6
of the 10 samples.
The predominance of isoform a in the PCR studies suggests
that this is the predominant isoform, and would suggest that
this isoform was down regulated at some point during malig-
nant transformation. However, the absence of novel exons
means that isoform speciﬁc probes cannot be made for probing
this cDNA panel, and this assumption could not be veriﬁed
using this technique. Therefore, in order to establish which iso-
forms of Bfk were being regulated, expression was studied by
PCR in matched cDNA pairs from tumour and normal colon
samples. In 3 out of 4 patients there appears to be a reduction
in expression of pro-apoptotic isoform a in the tumour sam-
ples compared to the normal tissues (Fig. 3C). This down reg-
ulation is consistent with the down regulation in 80% of the
colon samples on the cancer proﬁling array. In some cases
(e.g., patient one, isoform d) there is a very low level expres-
sion of other isoforms, which is also downregulated in the cor-
responding tumour samples. While this may represent
corresponding reduction in these isoforms, the eﬀect of the
reduction of isoform a is likely to be the most signiﬁcant. Thus,
downregulation of pro-apoptotic isoforms of Bfk is seen in the
majority of colorectal tumours examined, supporting the sug-
gestion that this protein may contribute to the protective eﬀect
of pro-apoptotic proteins against malignant transformation in
cells of the gastrointestinal tract.
It is our future aim to further study Bfk protein expression in
a large cohort of matched and well characterized colon cancer
samples, and to this end anti-Bfk antibodies were generated. A
polyclonal antibody raised to the N-terminal portion of Bfk
detects a band of appropriate size on immunoblots of colon
tissue (Fig. 4A). When immunoblots of various cancer cell
lines are examined by Western blotting using this antibody,
Fig. 3. Expression of Bfk isoforms in gastrointestinal tumours. (A) RT-PCR was performed on 2 lg mRNA from a number of cell lines derived from
human colon cancers using the primers SLRF1 and SLRR1 as before. Results shown are representative of four independent experiments. (B) A single
stranded radioactive cDNA probe to Bfk was hybridized to a membrane containing normalized cDNA from 154 tumour and corresponding normal
tissues from individual patients (BD Clontech) as described in Section 2. Bfk expression is largely restricted to tissue from the gastrointestinal tract
and is reduced in tumour tissue (lower row of each pair) compared to normal tissues (upper row) from the same patient. (C) PCR was performed on
cDNA from 4 matched tumour (T) and normal (N) colon samples (Clontech) using the primers described previously.
Fig. 4. Expression of human Bfk protein. (A) Expression in healthy
human colon samples: 50 lg commercial protein from a healthy colon
panel (Biochain) was subjected to 15% SDS–PAGE and probed with a
human anti-Bfk rabbit polyclonal antibody at a dilution of 1:1000. Bfk
is expressed in the transverse colon and the rectum. In vitro translated
Bfk isoform a is included for comparison. Results shown are
representative of two independent experiments. (B) Expression of
Bfk in cell lines derived from diﬀerent tissues: 50 lg total cell protein
from whole cell lysates was subjected to 15% SDS–PAGE and probed
with human anti-Bfk rabbit polyclonal antibody at a dilution of
1:1000. Ab80 was designed to detect Bfk isoform a and b. In vitro
translated isoforms were run alongside. Bfk isoform a is expressed in
HT-29, a colon adenocarcinoma cell line, but not MCF7 (breast cancer
cells), MEF (mouse embryonic ﬁbroblasts), Sy5y (neuroblastoma cells)
or CaCO2 (colon adenocarcinoma cell line).
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The epitope used to generate this antibody detects isoform a
and b, but not isoform c and d (Fig. 4B).
The exact function of Bfk isoforms in vivo, like many other
Bcl-2 family proteins, remains uncertain. The low level of
apoptosis induction by Bfk isoform a and b in overexpression
assays may indicate that further post-translational modiﬁca-
tion is required prior to full activity. The presence of a func-
tional caspase-cleavage site in isoform a and b suggests that
caspase cleavage may inﬂuence apoptosis, as it has been shown
to do for other Bcl-2 proteins [12–16]. In addition, potential
phosphorylation sites at serine-96 and serine-42 of Bfk might
further regulate function of Bfk.
Bfk exhibits a restricted tissue distribution similar to that
seen for Bcl-G [11] suggesting that these proteins are important
in both the sex hormone sensitive organs and the gastro-intes-
tinal tract. This oﬀers the tantalizing hint that these Bcl-2 pro-
teins may in part explain the reported links between sex
hormones and colorectal cancer [17].
The deregulation of genes involved in cell death is a necessity
for the development of cancer, and members of the Bcl-2 fam-
ily have been implicated in a variety of tumours, including
those of the gastrointestinal tract. The reduction in levels of
pro-apoptotic Bfk isoforms suggests that Bfk contributes to
the protection aﬀorded to cells of the gastrointestinal tract
by pro-apoptotic Bcl-2 family proteins.
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